Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
about
Implementing Genome-Driven Oncology.Targeted Lung Cancer Treatments and Eye MetastasisTargeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Recent Advances in Targeting ROS1 in Lung Cancer.Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a reviewKIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub.Targeting RET-rearranged lung cancers with multikinase inhibitors.Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.Molecular diagnostics of lung cancer in the clinic.Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.Molecular Targets in Non-Small Cell Lung Cancer.Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.Mechanisms of receptor tyrosine kinase activation in cancer.Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.Standardizing biomarker testing for Canadian patients with advanced lung cancer.Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.Colorectal cancer genomics and designing rational trials.The emerging treatment landscape of advanced non-small cell lung cancer.Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve LesionsRole of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
P2860
Q30235979-14BD954C-E6A4-4ADC-9EB1-EF19FDD97CD2Q33566410-DFAF7CE0-700A-4D2D-858D-BD0AF48828BAQ36356699-18881F0B-D426-40E6-AF90-E0EE27EB1704Q37743107-AA62425A-3F4D-4B70-A64B-FDB179F0C2F0Q38640765-B7A4AC89-0260-457B-A9AB-D5994A368279Q38718947-41AF360B-B36C-49D6-B1DA-75B4AA4225BEQ38724603-9E267166-F258-48A1-990C-80919EF0D63DQ38881066-B34F1B26-7463-4885-A99B-CE542A43C2EAQ39220897-8C8B4453-183C-4C80-B101-338AB1A54AFAQ41292062-BCEDE1F9-1547-403F-9CCB-C9CD3D4D2465Q41505056-1960DA46-6D24-4CEB-A32E-C39A73FBD435Q42347547-F6D88D8A-905F-45F1-ABA6-10176300A8B1Q42369856-F01CADF7-EA5F-4F8E-B6F7-B2F6C1130D18Q43690882-2DDE56BB-E9F9-47F5-8C48-45F5FA752D53Q45907759-AE1BC63F-9AFF-4FA7-8036-EFB167B6611EQ46299389-79803E73-C734-4FED-81C6-698FCB6D015DQ46512789-CC3D5C85-CB4D-467F-B55A-146751816EC8Q47104655-46A69BFB-1D70-4452-A5B5-A037C48394DEQ47137989-9E066AC5-B9C4-4F37-908F-C5D8BDBF73ECQ47139758-460535BE-0EDC-4910-A471-52147C5DBCC2Q47141828-7FEDD6B9-F6D9-43BB-A6B9-FD324DD086F8Q47151526-E7205790-610F-47F6-B0FD-B069A10E0D0DQ47159366-AE58D51F-2F9B-42EA-80E7-6A2AAED49F00Q47601932-CAB51EA0-1D4C-41BE-B80D-7D48C63C46F4Q48179589-474E753A-661B-4CB3-BCBC-8E8D2E6F5547Q49383683-F43D1278-F8B3-4E42-A016-EAF18AB2D071Q49887888-953ABD6D-2CBC-429F-B525-0993617B3081Q49888000-A2E674B1-13A6-42CA-BBAE-7AE923490A9CQ49953442-390C31D1-594E-4745-87FE-1434A4876392Q50251062-B7437B13-E449-4699-A31A-63684C736496Q51004850-70166915-DE3A-4782-ABDF-4185806521F3Q52312436-E24A1740-75E8-47A5-B53E-DEFD605D3E09Q52318443-5660BA2E-8EC6-444E-85D3-D856A31E2D08Q52587597-81117437-6CFB-496A-BA8C-2571DB497138Q52673091-0E5A951F-F5EF-497A-98B2-FE0614C88BFBQ54949177-AF9E3DB8-76E3-45EF-844A-BEBB73A34C4CQ55306266-59AA23A1-FD14-4072-88F6-198012E3D6F2Q55342455-5B72CC45-31FD-4A8D-BA57-6BEC3FB3900EQ57142923-DBD80EAE-AF69-4245-8CEE-AF4CC5E2214AQ57174372-ACBC8647-4577-47D8-8A19-86CF333EE32A
P2860
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Cabozantinib in patients with ...... re, phase 2, single-arm trial.
@en
type
label
Cabozantinib in patients with ...... re, phase 2, single-arm trial.
@en
prefLabel
Cabozantinib in patients with ...... re, phase 2, single-arm trial.
@en
P2093
P2860
P1433
P1476
Cabozantinib in patients with ...... re, phase 2, single-arm trial.
@en
P2093
Alexander Drilon
Andrew Plodkowski
Gregory J Riely
Joseph Montecalvo
Marc Ladanyi
Maria Arcila
Mark G Kris
Melanie Albano
P2860
P304
P356
10.1016/S1470-2045(16)30562-9
P577
2016-11-04T00:00:00Z